

healthymagination

- [healthymagination](#)
- [Challenge Home](#)
 - [About](#)
 - [Judges](#)
 - [Blog](#)
 - [Press](#)

[SIGN IN](#) | [REGISTER](#)

enter search enter search

- [Login](#)

e-mail

password

[forgot password?](#)

[Login](#)

Breast Cancer Pathways

Triple Negative Breast Cancer gp96-Ig Based Immunotherapy Cancer Vaccination

[6](#)



Heat Biologics has developed “Immune Pan-Antigen Cytotoxic Therapy” (ImPACT) for treatment of advanced cancers. ImPACT is an allogenic, gp96-Ig based immunotherapy that has proven safe and effective in a Phase I clinical trial for non-small cell lung cancer and is currently in Phase II trials. The strength of ImPACT's gp96-Ig approach is that it exposes the immune system to all of the antigens produced by a tumor cell bound to an immune-activating adjuvant. This provides a real advantage over other cancer vaccines that present only a single antigen or which lack an appropriate adjuvant. Given the promising results of ImPACT in lung cancer, Heat Biologics is initiating clinical trials for ImPACT against triple negative breast cancer (TNBC). We propose performing genechip genomic analyses of TNBC patients treated with Heat Biologics' ImPACT technology.

TNBC is the most difficult subtype of breast cancer to treat, as it does not respond to receptor-directed therapy. Personalized medicine and biomarker development can help deliver the right treatments to the right patients for specific disease subtypes such as TNBC. In addition, our genomic analyses will help clarify the basic mechanisms of action for immunotherapeutic vaccine therapy on heterogenous patient tumor tissue samples. Our team has significant experience in biomarker development in breast cancer patients receiving neoadjuvant cisplatin treatment. Our unique approach can determine outcomes in small cohorts of patients, and is optimal for supporting immune endpoint

analysis in early phase clinical trials. Conducting genomic analysis for the ImPACT TNBC trials will provide significant data for both patient indications and mechanisms of next generation cancer immunotherapies.

Submitted on
Nov 20, 2011

 Recommend

Share

 Tweet 3

#GEidea6545 

Sort By [Newest](#) 



From Twitter User: [@russell_hanson](#)

Please support my proposal w/ HeatBio Triple Negative Breast Cancer gp96-Ig Based Immuno Cancer Vaccination #GEidea6545 <http://t.co/nG1QOWqy>

2 days ago by [Healthymagination](#)

Similar Ideas



Personalized Immunotherapy for Triple Negative Breast Cancers



TARGETING TRIPLE NEGATIVE BREAST CANCER WITH A NEW COMBINATORIAL SMALL INTERFERING RNA STRATEGY




Injectable Probes for Improved Detection and Surgical Resection of Triple Negative Breast Cancer



Predictive Markers for the

Supporters



[Russell Hanson](#)

Development of
Personalized
Therapies for
Triple Negative
Breast Cancer



Targeting Triple
Negative
Breast Cancers
with Antibodies



© 2011 General Electric Company | [GE.com](#) | [Contact Us](#) | [Terms](#) | [FAQ](#) | [Privacy](#)

Powered by
BRIGHTIDEA

[Terms and Conditions](#) | Contact us: GEChallenge@brightidea.com

WebStorm[™]
POWERED BY
BRIGHTIDEA.COM

1.18302 seconds